Axonal damage markers in cerebrospinal fluid are increased in ALS

Area of Science:

• Neuroscience
• Biochemistry
• Clinical Neurology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron degeneration.
• Identifying reliable biomarkers for ALS subtypes and progression is crucial for effective treatment strategies and clinical trials.

Purpose of the Study:

• To investigate whether biomarkers of axonal degeneration correlate with clinical subtypes of ALS.
• To determine the utility of these biomarkers in predicting ALS progression.

Main Methods:

• A prospective study involving patients with ALS (n=69), Alzheimer's disease (AD; n=73), and age-matched controls (n=33).
• Cerebrospinal fluid (CSF) levels of tau protein and neurofilament light chain (NfL) were quantified using ELISA.
• Follow-up data were collected for 49 ALS patients over a median of 7 months.

Main Results:

• CSF NfL levels were significantly higher in ALS patients compared to controls and AD patients (p < 0.001).
• Elevated NfL levels were observed in patients with upper motor neuron-dominant ALS compared to typical ALS (p = 0.02).
• Higher NfL values correlated with more rapid ALS progression.

Conclusions:

• CSF biomarkers, particularly NfL, can potentially differentiate between ALS subtypes.
• These axonal degeneration markers may serve as valuable indicators for therapeutic trials in ALS.
• NfL demonstrated superior discriminatory power compared to tau protein.